In this study, we evaluated the potential of the neutrophil biomarkers PGLYRP1/TAG7, CAMP/LL37, MMP9, and CEACAM8/CD66b to predict DOX-induced cardiotoxicity in patients with early-stage breast cancer. This evidence concerns the gene MMP9 and breast cancer.